David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc., filed a Form 4 on August 24, 2026, reporting the exercise of stock options and the same-day sale of 25,000 shares of common stock.

Key Highlights

  • Option exercise: Krempa acquired 25,000 shares of common stock on August 24, 2026, via an employee stock option exercise (transaction code M) at an exercise price of $7.31 per share.
  • Same-day sale: Krempa disposed of 25,000 shares on August 24, 2026, at a weighted average price of $65.07 per share (transaction code S).
  • Sale price range: According to the filing, the shares were sold in multiple trades at prices ranging from $64.88 to $65.57.
  • Remaining ownership: Following the transactions, Krempa directly holds 37,025 shares of common stock.
  • Options remaining: Krempa retains 70,000 employee stock options, held directly, with an exercise price of $7.31 and an expiration date of February 19, 2029.
  • Option vesting: The filing states the exercised option vested in 48 equal monthly installments from the grant date of February 20, 2019, until fully vested.

Krempa's Option Exercise and Share Sale at Eton Pharmaceuticals

According to the Form 4 filed with the SEC on August 24, 2026, David Krempa, serving as Chief Business Officer of Eton Pharmaceuticals, Inc. (NASDAQ:ETON), reported two transactions in the company's common stock on the same date. First, Krempa exercised an employee stock option for 25,000 shares at an exercise price of $7.31 per share, temporarily bringing his directly held common stock position to 62,025 shares.

Immediately following the exercise, Krempa disposed of 25,000 shares through open-market sales. The filing reports a weighted average sale price of $65.07 per share, with individual trades occurring at prices ranging from $64.88 to $65.57. The filing notes that full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder. After these two transactions, Krempa's directly held common stock position stood at 37,025 shares.

In Table II of the filing, Krempa's remaining derivative securities are reported as 70,000 employee stock options, held directly, carrying an exercise price of $7.31 per share and an expiration date of February 19, 2029. The filing identifies the price of the derivative security as $0. The Form 4 was signed by Judith Matthews on Krempa's behalf on August 24, 2026, pursuant to an authorization described in the filing's remarks section.

What Was Disclosed

The filing discloses a same-day option exercise and share sale by Eton Pharmaceuticals' Chief Business Officer on August 24, 2026, resulting in a directly held position of 37,025 common shares and 70,000 remaining stock options.